Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Cuts Prices Of 463 Anticancers But Loose Ends Remain

Executive Summary

Prices of over 400 anticancers have been revised downwards in India by the capping of trade margins, but some healthcare activists say that real benefits for patients could still be elusive. Pharma is also required to maintain production volumes in the new scenario – will it pinch?


Related Content

New Window: India Extends Price Cap Exemption To Foreign Innovation
Regulator Warns Of Tougher Pricing Regime In India Amid ‘Market Failure’





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts